Leap Therapeutics Confirms Nasdaq Listing & Admin Details
Ticker: CYPH · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1509745
| Field | Detail |
|---|---|
| Company | Leap Therapeutics, INC. (CYPH) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, exchange-listing
TL;DR
**Leap Therapeutics just filed an 8-K confirming its Nasdaq listing and updated contact info.**
AI Summary
Leap Therapeutics, Inc. filed an 8-K on January 16, 2024, to update its registration information, specifically noting its Common Stock, par value $0.001, is traded on the Nasdaq Capital Market under the symbol LPTX. This filing primarily serves to confirm the company's current listing status and contact details, including its business address at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141. For investors, this matters because it reaffirms the company's compliance with exchange listing requirements and provides up-to-date administrative information, which is foundational for any publicly traded company.
Why It Matters
This filing confirms Leap Therapeutics' continued compliance with Nasdaq listing requirements, providing transparency and stability for current and prospective investors.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not contain any information that would introduce new financial or operational risks.
Analyst Insight
This filing is purely administrative and does not warrant any immediate investment action. Investors should continue to monitor operational and financial performance for actionable insights.
Key Numbers
- $0.001 — Par value per share (This is the nominal value assigned to each share of Common Stock.)
Key Players & Entities
- Leap Therapeutics, Inc. (company) — the registrant filing the 8-K
- Nasdaq Capital Market (company) — the exchange where Leap Therapeutics' stock is registered
- LPTX (company) — the trading symbol for Leap Therapeutics' Common Stock
- $0.001 (dollar_amount) — par value of Common Stock
- January 16, 2024 (date) — date of earliest event reported and filing date
Forward-Looking Statements
- Leap Therapeutics will maintain its listing on the Nasdaq Capital Market. (Leap Therapeutics, Inc.) — high confidence, target: 2025-01-16
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is Leap Therapeutics, Inc.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 16, 2024.
What is the trading symbol for Leap Therapeutics, Inc.'s Common Stock?
The trading symbol for Leap Therapeutics, Inc.'s Common Stock is LPTX.
On which exchange is Leap Therapeutics, Inc.'s Common Stock registered?
Leap Therapeutics, Inc.'s Common Stock is registered on the Nasdaq Capital Market.
What is the par value of Leap Therapeutics, Inc.'s Common Stock?
The par value of Leap Therapeutics, Inc.'s Common Stock is $0.001.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-01-16 17:10:22
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 LPTX Nasdaq Capital Market Indicate
Filing Documents
- tm243430d1_8k.htm (8-K) — 26KB
- tm243430d1_ex99-1.htm (EX-99.1) — 21KB
- tm243430d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-004162.txt ( ) — 228KB
- lptx-20240116.xsd (EX-101.SCH) — 3KB
- lptx-20240116_lab.xml (EX-101.LAB) — 33KB
- lptx-20240116_pre.xml (EX-101.PRE) — 22KB
- tm243430d1_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On January 16, 2024, Leap Therapeutics, Inc. (the "Company") issued a press release entitled "Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium." The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference; provided, however that information on or connected to our website referenced in the Company's press release is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated January 16, 2024. 104 Cover Page Interactive Data File. (Embedded within the Inline XBRL document.) - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: January 16, 2024 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Executive Officer and President